Document is current
Any future updates will be listed below
-
Authors
,
Colombo, Marco
McGurnaghan, Stuart J.
Blackbourn, Luke A. K.
Dalton, R. Neil
Dunger, David
Bell, Samira
Petrie, John R.
Green, Fiona
MacRury, Sandra
McKnight, John A.
Chalmers, John
Collier, Andrew
McKeigue, Paul M.
Colhoun, Helen M. https://orcid.org/0000-0002-8345-3288
-
Funding
Funding for this research was provided by:
Diabetes UK (Ref. 10/0004010)
Chief Scientist Office (Ref. ETM/47)
Juvenile Diabetes Research Foundation (Ref. 3-SRA-2016- 332-M-R)
- License Information
-
More Information
Article History
Received: 2 September 2019
Accepted: 2 December 2019
First Online: 8 January 2020
Duality of interest
: HMC has received grants, personal fees and non-financial support from Eli Lilly & Company, grants from Pfizer Inc., grants from Boehringer Ingelheim, grants from AstraZeneca LP, grants, personal fees and non-financial support from Sanofi, non-financial support from Novartis Pharmaceuticals, personal fees and non-financial support from Regeneron, has received grants and holds shares at Roche Pharmaceuticals, is a shareholder in Bayer, has received non-financial support from Sanofi Aventis, outside the submitted work. RND is a shareholder of SpOtOn Clinical Diagnostics Ltd. MC, SJM, LAKB, DD, SB, JRP, SMacR, JAMcK, JC, AC and PMM declare that there is no duality of interest associated with their contribution to this manuscript. The study sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
